Celgene Corp
Most Recent
What Were the Top Holdings of Citadel Advisors in Q3?
In Q3 2019, Citadel Advisors’ portfolio of publicly traded securities was worth $212.04 billion. In Q2 2019, its portfolio was worth $155.1 billion.
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
The George Soros Fund Shares 13F Analysis
On November 14, The George Soros Fund Management LLC filed 13F. The firm’s total market value was around $3.6 billion at the end of Q3 2019.
Renaissance Technologies: Analyzing Its Q3 13F
At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.
Analyzing Tudor Investment’s Top Holdings
Tudor Investment founder Paul Tudor Jones II’s macro investment strategies have helped investors understand the opportunities in various securities.
Renaissance Technologies: Top Investments
Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.
Amgen and Celgene’s Otezla Deal: Key Highlights
On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.
Bristol-Myers Squibb’s Oncology Treatment Growth Drivers
Revenue for Bristol-Myers Squibb’s (BMY) Opdivo has grown by a double-digit percentage YoY (year-over-year) since 2016.
How PFE’s and BMY’s EPS Trends Compare
In fiscal 2019, Pfizer (PFE) expects its adjusted diluted EPS to fall 4.0% YoY (year-over-year) to $2.83–$2.93.
What Analysts Recommend for Bristol-Myers Squibb and Celgene
The consensus recommendation for Bristol-Myers Squibb is a “buy,” while the consensus for Celgene is a “hold.”
What Analysts Recommend for Bristol-Myers Squibb and Celgene
The current consensus analyst recommendation for Bristol-Myers Squibb is a “buy.”
What’s the Latest on the BMY-Celgene Deal?
Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.
Roche Holdings to Acquire Spark Therapeutics
On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).
ABBV or CELG: Comparing Dividends, Interest Expenses, and Debt
AbbVie (ABBV) and Celgene (CELG) reported dividends per share of $3.59 and $0.0, respectively, in 2018.
AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?
On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.
Is AbbVie or Celgene Expected to Report Faster Revenue Growth?
On January 3, Bristol-Myers Squibb (BMY) issued a press release announcing that it had entered into a definitive agreement to acquire Celgene.
What Analysts Recommend for AbbVie and Celgene This Month
On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77.
Revlimid and Pomalyst Continued to Be Growth Drivers for Celgene
On January 7, 2019, Celgene (CELG) issued a press release announcing its strategy to maximize the commercial potential of its major revenue-earning hemato-oncology assets.
Can Celgene’s Revenues Impress the Market in Q4 2018?
On January 7, Celgene (CELG) issued a press release announcing that the company earned revenues of $15.2 billion for fiscal 2018.
Ray Dalio’s Advice Is to ‘Go Counter-Cyclical’
Ray Dalio thinks of the markets in the context of the economic machine, wherein cycles repeat themselves.
Celgene and Bristol-Myers Squibb’s Deal: What Are the Benefits?
Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.
Key Growth Drivers for Bristol-Myers Squibb Going Forward
Bristol-Myers Squibb (BMY) will target four major therapeutic areas after completing the acquisition of Celgene (CELG).
BMY and Celgene to Form a Leading Global BioPharma Company
According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.
Bristol-Myers Squibbs and Celgene: Cost Synergies for Future Years
According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.
What to Expect from Bristol-Myers Squibb’s Earnings in 2019
Bristol-Myers Squibb (BMY) expects to report GAAP EPS in the range of $3.05 to $3.15 and non-GAAP EPS in the range of $3.80 to $3.90 for fiscal 2018.
How Bristol-Myers Squibb’s Revenues Look Heading into 2019
In its third-quarter earnings conference call, Bristol-Myers Squibb (BMY) has forecasted high-single-digit YoY revenue growth for fiscal 2018.
What to Expect from BMY’s Celgene Acquisition
The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.
Bristol-Myers Squibb to Acquire Celgene
Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.
Let’s Talk about Bristol-Myers Squibb’s 2019 EPS Guidance
Today, Bristol-Myers Squibb (BMY) is trading at $45.85, ~11.86% lower than its previous day’s closing price.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
A Look at Abraxane’s Revenue Growth Trajectory in 2018
In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.
A Look at Pomalyst’s Revenue Growth Trajectory in 2018
In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Pomalyst fiscal 2018 net product sales of around $2.0 billion.
A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018
On October 23, 2018, Celgene issued a press release announcing favorable results from open-label Phase 2/3 trial, ECOG E3A06, evaluating Revlimid in the smoldering multiple myeloma (or MM) indication.
What’s Revlimid’s Revenue Growth Trajectory in 2018?
In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Revlimid’s fiscal 2018 net product sales of around $9.7 billion.
Inflammation and Immunology: Celgene’s Diversified Research Pipeline
Celgene (CELG) is focused on advancing its diversified inflammation and immunology (or I&I) research pipeline in 2018.
Celgene Eyes Opportunities for Otezla
In the first nine months of 2018, Celgene’s (CELG) Otezla reported worldwide sales of $1.16 billion.
Otezla to Be Major Growth Driver for Celgene in 2018
In its third-quarter earnings conference call, Celgene (CELG) has revised its fiscal 2018 net product sales guidance for Otezla from the previously projected $1.5 billion to $1.6 billion.
What Are Celgene’s Margin Projections for Fiscal 2018?
In its third-quarter earnings conference call, Celgene (CELG) revised its GAAP operating margin guidance for fiscal 2018 from 35% to 34%.
What Analysts Recommend for Celgene and Peers in November
Celgene reported Q3 revenues of $3.89 billion, a YoY rise of 18.2%. The company managed to surpass consensus revenue estimates by $40 million.
Why Has AstraZeneca’s Stock Price Increased in 2018?
On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.
How Wall Street Analysts View Merck
On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.
How Celgene’s Otezla, Abraxane, and Other Drugs Performed
Celgene’s (CELG) Otezla reported revenues of $432.0 million in the third quarter, a ~40.3% YoY increase.
Analysts Expect Incyte to Report Revenue Growth in Third Quarter
Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.
Johnson & Johnson’s Oncology Business Saw Solid Growth in Q3
Johnson & Johnson’s (JNJ) oncology business generated revenue of $2.6 billion in the third quarter.
Biogen: Analysts’ Recommendations on October 19
For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Celgene: Multiple Myeloma Franchise Could Drive Growth
In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid.
Celgene’s Financial Position before Its Third-Quarter Earnings
Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.
Cara Therapeutics: Performance and Estimates for Q3
Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.
Allergan’s Stock Performance and Estimates for Q3 2018
Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.
Ionis Pharmaceuticals’ Revenue Stream
Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.
Allergan’s Developments in September
On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.
Here Are the Key Products in Sage’s GABA Receptor Portfolio
Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.
How Celgene’s Gene Therapy Business Is Positioned
Celgene has completed patient enrolment in TRANSCEND, a Phase 1/2 trial evaluating JCAR017 for treating diffuse large B-cell lymphoma.
A Performance Update on Roche’s Pharmaceuticals Segment in August
Roche’s (RHHBY) Pharmaceuticals division reported revenues of 21.8 billion Swiss francs in H1 2018 compared to 20.5 billion Swiss francs in H1 2017, reflecting ~7% YoY growth.
Analyst Recommendations for Biogen and Its Peers in August
On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401 in early Alzheimer’s disease.
Recent Developments at Allergan
Allergan (AGN) is developing a variety of products through internal programs as well as in collaboration with other companies.
Considering Allergan’s Q2 2018 Revenue Trend
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.
A Financial Overview of Bausch Health Companies in August
Bausch Health Companies reported revenue of $2.1 billion in the second quarter, reflecting a ~5% YoY (year-over-year) fall and a ~3% YoY organic rise.
What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.
What to Expect from Sarepta’s Second-Quarter Earnings
Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.
A Look at Merck’s Financial Position
In the second quarter of 2018, Merck (MRK) generated revenues of $10.5 billion, which reflected 5% growth on a year-over-year (or YoY) basis and 4% growth sequentially.
Eli Lilly’s Neuroscience Products Sales Dropped in Q2 2018
Zyprexa reported revenues of $128.0 million in Q2 2018, a 9.0% decline in YoY revenues compared to $140.8 million in Q2 2017.
Shire’s Q2 2018 Earnings Beat Analyst Estimates
Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.
Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.
What Analysts Recommend for Bluebird Bio Stock
As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.
What Alnylam’s Bottom Line Is Expected to Look Like in Q2 2018
Alnylam Pharmaceuticals’ (ALNY) selling, general, and administrative expenses are expected to rise 73.46%.
Merck Witnessed 5% Growth in Q2 2018
Merck (MRK) generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year growth.
Amgen Beats Estimates, Reports Growth in Q2 2018
Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.
Celgene Raises Revenue Guidance after Solid Growth in Q2 2018
In the second quarter of 2018, Celgene (CELG) reported revenues of $3.8 billion, compared to $3.3 billion in the second quarter of 2017.
Why Most Analysts Are Bullish on Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) is expected to incur selling, general, and administrative expenses of $117.10 million in Q2 2018 as compared with $92.91 million in Q2 2017.
What Gilead Sciences’ Bottom Line Is Expected to Look Like in Q2
Gilead Sciences’ (GILD) research and development expenses are expected to increase 8.78%, from $812 million in Q2 2017 to $883.27 million in Q2 2018.
What Analysts Think about AstraZeneca and Peers in July
AstraZeneca (AZN) is expected to incur research and development expenses of $1.26 billion in Q2 2018 as compared with $1.28 billion in Q2 2017.
How Are Celgene’s Multiple Myeloma Drugs Positioned before Q2?
Celgene’s (CELG) Revlimid and Pomalyst generated revenues of $2.2 billion and $453 million, respectively in the first quarter.
Why Most Analysts Recommend a ‘Buy’ for Alexion Stock
Analysts expect Alexion Pharmaceuticals’ (ALXN) interest expense to decline by 5.32% from $24 million in Q2 2017 to $22.72 million in Q2 2018.
Darzalex Could Boost JNJ’s Revenue Growth in 2018
Johnson & Johnson’s (JNJ) Darzalex generated revenues of $432.0 million in Q1 2018 compared to $255.0 million in Q1 2017, reflecting ~69.4% YoY growth.
Acceleron Pharmaceuticals and Celgene Rise on Meeting Study Goals
Today, Celgene (CELG) and Acceleron Therapeutics (XLRN) stocks are trending higher on the news of their Phase 3 clinical trial for luspatercept meeting its goal.
Amgen Announced the Phase 3 Results for ABP 710
On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.
Celgene’s CAR T Cell Therapy Could Be Long-Term Growth Driver
In June 2018, Celgene (CELG) and Bluebird Bio (BLUE) presented updated results from the ongoing phase 1 CRB-401 trial of bb2121.
Why Editas Medicine Fell 7.8% on Monday
On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.
TrovaGene Stock Fell 48% on June 8 after Pricing Announcement
Following TrovaGene’s pricing announcement, the stock price decreased ~48% to the closing price of $0.92 on June 8.
Why Sesen Bio Stock Jumped Over 37% this Week
Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.
Amgen Focused on Advancing Oncology Research Programs in 2018
The FDA approved Amgen’s Blincyto to treat MRD greater than or equal to 0.01% in B-cell precursor ALL patients.
What Drove Ionis’s Revenue in Q1
In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.
What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?
Scynexis (SCYX) witnessed a 28% rise in its stock price in the week ended May 18.
Amgen Stock Rises over 2% on Drug Approvals
Amgen (AMGN) stock has risen ~2.3% in the last week following recent drug approvals.
BlueBird Bio Stock Jumps over 6% on May 17
BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.
How Much Upside Do Analysts See in Alexion Stock?
Of the 19 analysts covering Alexion Pharmaceuticals in May, 18 have given the stock “buy” or higher ratings.
How Much Upside Potential Does Celgene Offer?
Of the 30 analysts covering Celgene in May, 15 analysts rated the stock a “buy” or higher, and 14 analysts gave Celgene a “hold” rating.
Exploring Celgene’s Promising Research Pipeline
Celgene entered into a collaboration with BeiGene Limited for advancing the BGB-A317 program, which is targeted at solid tumor cancers.
Celgene’s Otezla Witnessed Solid Growth in 1Q18
In 1Q18, Celgene’s (CELG) Otezla generated revenue of $353 million compared to $242 million in 1Q17.
How Celgene Performed in 1Q18
In 1Q18, Celgene’s (CELG) revenue grew 20% year-over-year to $3.5 billion from $3.0 billion, boosted by Revlimid, Pomalyst, and Otezla sales.
Kyprolis Is Expected to Boost Amgen’s Revenue Growth
In 1Q18, Amgen’s (AMGN) Kyprolis revenue grew 17% YoY (year-over-year) to $222 million from $190 million, primarily due to higher unit demand in international markets.
18 Earnings Reports We’re Watching Closely Next Week
Last big week of earnings kicks off with not a lot to show for it in the market The week of April 30 is an exciting one in terms of earnings, and here are 18 companies we will be watching closely: Monday McDonald’s Corporation (NYSE: MCD) – before the market opens – great year last […]
Eliquis and Xeljanz: Key Growth Drivers for Pfizer in 2018
In 2017, Pfizer (PFE) earned $2.5 billion from sales of Eliquis through direct sales and through its alliance with Bristol-Myers Squibb.
Allergan’s 1Q18 Earnings: Analysts’ Estimates
Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.
Otezla: Shoring Up Celgene’s Top Line
Celgene’s Otezla has been approved for the treatment of psoriatic arthritis and psoriasis in US, Japanese, EU, and other markets.
Novartis Enters Agreement to Acquire AveXis
On April 9, 2018, Novartis AG announced that it had entered into an agreement to acquire AveXis for ~$8.7 billion.
Celgene Stock Performance in 1Q18
Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months.
Pharma’s Latest: Mergers and Acquisitions in 1Q18
Let’s take a look at the mergers and acquisitions that took place in the US pharmaceutical sector in 1Q18.